Cargando…
Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model
BACKGROUND: Several treatment alternatives are available for primary breast cancer, although those for metastatic disease or inflammation associated with tumor progression are ineffective. Therefore, there is a great need for new therapeutic alternatives capable of generating an immune response agai...
Autores principales: | Urueña, Claudia, Mancipe, Juan, Hernandez, John, Castañeda, Diana, Pombo, Luis, Gomez, Alejandra, Asea, Alexzander, Fiorentino, Susana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626639/ https://www.ncbi.nlm.nih.gov/pubmed/23552194 http://dx.doi.org/10.1186/1472-6882-13-74 |
Ejemplares similares
-
A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line
por: Castañeda, Diana M, et al.
Publicado: (2012) -
An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma
por: Lasso, Paola, et al.
Publicado: (2020) -
Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells
por: Urueña, Claudia, et al.
Publicado: (2008) -
Safety Evaluation in Healthy Colombian Volunteers of P2Et Extract Obtained from Caesalpinia spinosa: Design 3+3 Phase I Clinical Trial
por: Duran, María I, et al.
Publicado: (2022) -
Safety and efficacy of P2Et extract from Caesalpinia spinosa in breast cancer patients: study protocol for a randomized double blind phase II clinical trial (CS003-BC)
por: Ballesteros-Ramírez, Ricardo, et al.
Publicado: (2023)